When a patient’s anxiety manifests as persistent fears about their health, it can make them difficult to treat.

In 2001, the APA published its first attempt to establish evidence-based guidelines for the treatment of BPD. In 2025, an ...

Purpose: Generalized Anxiety Disorder (GAD) is a common mental disorder ... adequacy based on recommendation from clinical practice guidelines; 3) examine correlates of treatment adequacy, i.e ...

US-based biotechnology company Mind Medicine (MindMed) has dosed the first subject in the 52-week Phase III Voyage study of ...

PHOENIXVILLE, PA — Facet Life Sciences has been selected as the U.S. regulatory partner for Cybin Inc., a neuropsychiatry ...

About Generalized Anxiety Disorder (GAD) GAD is a common condition associated with significant impairment that adversely affects millions of people. GAD results in fear, continuing anxiety ...

Voyage is the first of two Phase 3 studies in GAD evaluating the efficacy and safety ... and ethical standards and are in alignment with guidance from the U.S. Food and Drug Administration ...

The MM120 ODT Phase 3 clinical development program includes the Voyage and Panaroma studies in generalized anxiety disorder (GAD) and the Emerge study in major depressive disorder (MDD).

Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...